A Combination of Avutometinib Plus Defactinib Results in Clinically Meaningful Benefit in Patients with Recurrent Low-Grade Serous Ovarian Cancer By Ogkologos - August 5, 2025 598 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ENGOT-OV60/GOG-3052/RAMP 201 study Source RELATED ARTICLESMORE FROM AUTHOR Population-based lung cancer screening can reduce mortality in people who have never smoked, study shows in China Efficacy of Romiplostim In the Treatment and Prevention of Recurrence of Persistent Chemotherapy-Induced Thrombocytopenia FDA Approves Teclistamab in Combination with Daratumumab Hyaluronidase-fihj for Relapsed or Refractory Multiple Myeloma MOST POPULAR NECTIN4 Amplification Predicts Response to Enfortumab Vedotin and Long-Term Survival in... May 8, 2024 Adjuvant Nivolumab Plus Ipilimumab Combination Does Not Improve RFS Over Nivolumab... October 4, 2022 Five Questions With…Amber. June 30, 2022 Fostering Growth and Creativity Through Journaling August 11, 2021 Load more HOT NEWS Dual Antigen Targeting with Talquetamab plus Teclistamab in Patients with Relapsed... Marine Runs Five Marathons in Five Days to Help Fund Sister’s... Apalutamide Plus ADT Provides Significant Improvement in Overal Survival and Delays... Enfortumab Vedotin Approved for Recurrent Bladder Cancer
